PMID- 29733433
OWN - NLM
STAT- MEDLINE
DCOM- 20181015
LR  - 20181015
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 43
IP  - 4
DP  - 2018 Aug
TI  - Statin therapy on glycemic control in type 2 diabetic patients: A network 
      meta-analysis.
PG  - 556-570
LID - 10.1111/jcpt.12690 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Statins are the cornerstone of primary and secondary 
      prevention of cardiovascular diseases (CVDs) and are effective for the prevention 
      of vascular events in diabetic patients. Diabetes mellitus is an important risk 
      factor for CVDs .The majority of patients with diabetes mellitus benefits from 
      statin therapy. According to the recent clinical guidelines of the American 
      College of Cardiology and the American Heart Association, moderate-intensity or 
      high-intensity statin therapy should be used as the primary prevention for 
      individuals with diabetes mellitus, aged between 40 and 75 years and with 
      low-density lipoprotein cholesterol (LDL-C) from 70 to 189 mg/dL. The objective 
      of this review was to compare the associations of individual statins with their 
      adverse effects on glycemic control in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: MEDLINE, EMBASE and CENTRAL were searched from inception through 
      March 2017. There were included randomized controlled trials comparing statins 
      with placebo or active comparators in patients with T2DM. The endpoints of 
      interest were glycated haemoglobin A1(C) (HbA1(C) ) and fasting plasma glucose 
      (FPG). We performed a pairwise meta-analysis and a network meta-analysis within a 
      frequentist framework. The standard mean differences (SMD) and 95% confidence 
      intervals (CI) were calculated. RESULTS: Twenty-three trials were included. A 
      significant increase in HbA1c was detected in the pairwise meta-analysis when 
      statins as a class were compared with placebo (SMD: 0.11). Moderate-intensity 
      pitavastatin lowered HbA1c compared with moderate-intensity atorvastatin (SMD: 
      -0.16), high-intensity atorvastatin (SMD: -0.77), moderate-intensity rosuvastatin 
      (SMD: -0.16) and low-intensity pravastatin (SMD: -0.15). Moderate-intensity 
      simvastatin lowered HbA1c compared with high-intensity rosuvastatin (SMD: -0.45) 
      and high-intensity atorvastatin (SMD: -0.77). High-intensity atorvastatin 
      elevated HbA1c compared with placebo (SMD: 0.63), moderate-intensity rosuvastatin 
      (SMD: 0.50), low-intensity pravastatin (SMD: 0.51) and moderate-intensity 
      atorvastatin (SMD: 0.50). Moderate-intensity pitavastatin has lowered FPG 
      compared with placebo (SMD: -0.55), moderate-intensity rosuvastatin (SMD: -0.65), 
      moderate-intensity atorvastatin (SMD: -0.65) and high-intensity atorvastatin 
      (SMD: -1.25). High-intensity atorvastatin has elevated FPG compared with placebo 
      (SMD: 0.70), moderate-intensity atorvastatin (SMD: 0.60), moderate-intensity 
      rosuvastatin (SMD: 0.60) and moderate-intensity simvastatin (SMD: 0.90). WHAT IS 
      NEW AND CONCLUSION: Statins were associated with an increase in HbA1c compared 
      with placebo. In patients with T2DM, moderate-intensity pitavastatin improved the 
      glycemic control whereas high-intensity atorvastatin worsened it. Appropriate 
      statins should be administered for patients with diabetes mellitus.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Cui, J Y
AU  - Cui JY
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Zhou, R R
AU  - Zhou RR
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Han, S
AU  - Han S
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Wang, T S
AU  - Wang TS
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Wang, L Q
AU  - Wang LQ
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Xie, X H
AU  - Xie XH
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180507
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Blood Glucose)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/*drug effects
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Middle Aged
MH  - Network Meta-Analysis
MH  - Risk Factors
MH  - Secondary Prevention/methods
OTO - NOTNLM
OT  - HbA1c
OT  - fasting plasma glucose
OT  - glycemic
OT  - network meta-analysis
OT  - statin
OT  - type 2 diabetes
EDAT- 2018/05/08 06:00
MHDA- 2018/10/16 06:00
CRDT- 2018/05/08 06:00
PHST- 2017/11/05 00:00 [received]
PHST- 2018/03/23 00:00 [accepted]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2018/10/16 06:00 [medline]
PHST- 2018/05/08 06:00 [entrez]
AID - 10.1111/jcpt.12690 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2018 Aug;43(4):556-570. doi: 10.1111/jcpt.12690. Epub 2018 May 
      7.